Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Breast 1

Conditions

Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Sarcoma 1Lung Neoplasms 1Liver Neoplasms 1Liver Cirrhosis 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms 1

Interventions

Carboplatin 42Etoposide 37Cisplatin 23Topotecan 22Nivolumab 17pembrolizumab 12atezolizumab 12Ipilimumab 10Paclitaxel 9durvalumab 8Irinotecan 8Radiosurgery 6Pemetrexed 6rovalpituzumab tesirine 5Magnetic Resonance Spectroscopy 5trioctyl phosphine oxide 4trilaciclib 4etoposide phosphate 4berzosertib 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4Dexamethasone 4veliparib 3tremelimumab 3olaparib 3carfilzomib 3cabozantinib 3Temozolomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Small Cell Lung Carcinoma × fluoromisonidazole × Clear all
NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
122 enrolled 16 charts
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00544674 2012-12-10

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Proacta, Incorporated

Phase 2 Terminated
5 enrolled 7 charts
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡